Compare KOSS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOSS | RFL |
|---|---|---|
| Founded | 1953 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Real Estate |
| Sector | Consumer Staples | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 61.1M |
| IPO Year | 1994 | 2017 |
| Metric | KOSS | RFL |
|---|---|---|
| Price | $4.08 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.3K | ★ 91.0K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.00 | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,624,170.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.93 | ★ 43.96 |
| 52 Week Low | $4.00 | $1.12 |
| 52 Week High | $8.59 | $3.19 |
| Indicator | KOSS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 65.63 |
| Support Level | $4.07 | $1.41 |
| Resistance Level | $5.04 | $1.63 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 22.37 | 71.25 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.